ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2023
Retrieved on:
Wednesday, May 10, 2023
Medicine, HOPE, Genomics, Glomus tumor, DSM-IV codes, Hospital, Patient, Borderline personality disorder, R, ALS, Charcot–Marie–Tooth disease, Columbia University, LSD1, Human, IDMC, Platinum, Innovation, Research, NET, CMT, Kabuki syndrome, Phase, FDA, IND, Conference, Safety, Duration, Schizophrenia, Seaver Autism Center, Measure (mathematics), Mental health, Deficit spending, ORY, FCCC, Dor, FMS, Hospital Universitario La Paz, BPD, Fox Chase Cancer Center, Clinical trial, Paclitaxel, CNS, Icahn School of Medicine at Mount Sinai, Hospital das Clínicas, AML, Mount Sinai Hospital, Spectrum, ISIN, ICMJE recommendations, Treatment, Pharmaceutical industry, Nursing, Video game, Science, SCLC
Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon has made strong clinical progress in the first quarter this year.
Key Points:
- Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon has made strong clinical progress in the first quarter this year.
- Research and development (R&D) expenses were $4.4 million for the quarter ended March 31, 2023, compared to $4.2million for the quarter ended March 31, 2022.
- General and administrative expenses were $1.2 million for the first quarter ended March 31, 2023, compared to $1.3 million for the first quarter ended March 31, 2022.
- Net losses were $1.4 million for the first quarter ended March 31, 2023, compared to $1.7 million for the first quarter ended March 31, 2022.